Imara
Pioneering therapeutic advancements with innovative solutions for rare genetic hemoglobin disorders.
General Information
BounceWatch is an independent company data service, not affiliated with Imara. To contact Imara, visit imaratx.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Imara compare?
A PDF of Imara and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Imara soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
About Imara
Business keywords: therapeutics, genetic disorders, hemoglobin, IMR-687, PDE9 inhibitor, sickle cell disease, beta-thalassemia, clinical-stage, multimodal mechanism of action, red blood cells, white blood cells, adhesion mediators, rare diseases, innovative treatments
Funding Rounds & Investors (4)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Equity | $50.00M | - |
|
14 Jul 2021 |
| Series B | $63.00M | 9 |
|
18 Mar 2019 |
| Series A | $31.00M | 1 |
|
14 Apr 2016 |
| Seed Round | $800.00K | - |
|
01 Jan 2016 |
Imara Alternatives & Competitors
View All Alternatives
We are a clinical-stage biotechnology company developing treatments that transform patients’ lives.
Improving the lives of people with rare disease.
Pursuing curative gene therapies to give patients and their families more bluebird days.
FAQ About Imara
Source: BounceWatch company record for Imara, https://bouncewatch.com/company/imara, updated 27 October 2024. When citing, please name BounceWatch and link this page.
